Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARα acute promyelocytic leukemia (APML)
- 125 Downloads
Patients with acute promyelocytic leukemia (APML) with the t(11;17) translocation usually respond poorly to all-trans retinoic acid (ATRA) and chemotherapy. We describe a patient with promyelocytic leukemia zinc finger/retinoic acid receptor alpha (PLZF/RARα) APML who was treated with combination chemotherapy after poor response to arsenic trioxide. He achieved hematological remission in 4 weeks followed by achievement of molecular remission in 8 weeks. Four cycles of consolidation chemotherapy followed by four cycles of maintenance therapy were given over a period of 9 months. At a follow-up of 32 months after achieving hematological remission, he continues to remain in hematological and molecular remission with normal blood parameters and negative reverse transcriptase polymerase chain reaction (RT-PCR) results. Combination chemotherapy can achieve sustained remission in patients with PLZF/RARα APML.
KeywordsPLZF/RARα APML Chemotherapy Molecular remission
- 1.Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, Waxman S, Zelent A (1993) Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J 12:1161–1167PubMedGoogle Scholar
- 5.Jansen JH, de Ridder MC, Geertsma W, Erpelinck CA, van Lom K, Smit EM, Slater R, van der Reijden BA, de Greef GE, Sonneveld P, Lowenberg B (1999) Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 94:39–45PubMedGoogle Scholar
- 6.Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E (1997) Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90:4876–4885PubMedGoogle Scholar
- 11.Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, de The H (1999) Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 18:1113–1118CrossRefPubMedGoogle Scholar